12 March 2020 - NICE has published a new final draft guidance recommending against the routine use of Keytruda (pembrolizumab) locally advanced or metastatic urothelial carcinoma.

The rejection, which would have been for adults who have had platinum-containing chemotherapy, comes after a review of new evidence collected while the MSD blockbuster was available via the Cancer Drugs Fund.

NICE says that there is still uncertainty surrounding the long-term benefit of the second-line immunotherapy treatment in comparison with other options, meaning it is not a “cost-effective use of NHS resources at its current price.”

Read Pharma Times article